orbofiban has been researched along with Thrombopenia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, CS; Cines, DB | 1 |
| Aster, RH; Brassard, JA; Cannon, CP; Cooper, RA; Curtis, BR; Ehardt, M; Ferguson, J; Komocsar, W; Kupfer, S; Maurath, C; Swabb, E | 1 |
| Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM | 1 |
| Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
| Jang, IK; Sabatine, MS | 1 |
2 review(s) available for orbofiban and Thrombopenia
| Article | Year |
|---|---|
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Autoimmunity; Benzamidines; Humans; Immunoglobulin Fab Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Thrombocytopenia; Thrombosis | 2002 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
3 trial(s) available for orbofiban and Thrombopenia
| Article | Year |
|---|---|
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Topics: Acute Disease; Alanine; Autoantibodies; Autoimmunity; Benzamidines; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Risk Factors; Thrombocytopenia | 2002 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombocytopenia; Thrombosis | 2006 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |